DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026)
DiaMedica Therapeutics (DMAC) reported Receivables of $586000.0 for Q1 2026, up 21.58% on a YoY basis from $482000.0 in Q1 2025, and up 15.35% quarter-over-quarter from $508000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Receivables for 10 years, with the latest figure at $586000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 21.58% year-over-year to $586000.0; the trailing twelve-month figure through Mar 2026 stood at $586000.0 (up 21.58% YoY), and the FY2025 full-year result was $266000.0, up 12.24% from the prior year.
- Receivables for Q1 2026 stood at $586000.0, up from $508000.0 in the prior quarter.
- The five-year high for Receivables was $790000.0 in Q1 2024, with the low at $75000.0 in Q3 2022.
- Historically, Receivables has averaged $404470.6 across 5 years, with a median of $440000.0 in 2023.
- The largest YoY upside for Receivables was 725.33% in 2023 against a maximum downside of 66.47% in 2023.
- DiaMedica Therapeutics' Receivables stood at $84000.0 in 2022, then surged by 423.81% to $440000.0 in 2023, then tumbled by 46.14% to $237000.0 in 2024, then soared by 114.35% to $508000.0 in 2025, then rose by 15.35% to $586000.0 in 2026.
- The last three Receivables figures came in at $586000.0 (Q1 2026), $508000.0 (Q4 2025), and $488000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - | 586,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 586,000.00 |
| Dec 31, 2025 | 508,000.00 |
| Sep 30, 2025 | 488,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 578,000.00 |
| Jun 30, 2024 | 778,000.00 |
| Mar 31, 2024 | 790,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 619,000.00 |
| Jun 30, 2023 | 374,000.00 |
| Mar 31, 2023 | 112,000.00 |
| Dec 31, 2022 | 84,000.00 |
| Sep 30, 2022 | 75,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 334,000.00 |
| Dec 31, 2021 | 130,000.00 |
| Sep 30, 2021 | 206,000.00 |
| Jun 30, 2021 | 32,000.00 |